Macular Degeneration clinical trials at UC Davis
3 research studies open to eligible people
A Study of Age-Related Macular Degeneration (vision loss) and Reticular Pseudodrusen (yellow pattern in the vision part of eye)
open to eligible people ages 55 years and up
Objective: To learn more about AMD. Eligibility: People ages 55 and older with any of the following: AMD or changes in the retina that put them at risk for AMD RPD Healthy eyes Design: Participants will be screened with: Eye exam: The pupil will be dilated with eye drops. Eye pressure and movements will be checked. Pictures will be taken of the inside of the eye. Reading an eye chart. Optical coherence tomography (OCT): The eyes are dilated. A machine measures the thickness of the retina. Participants will have a first visit that includes: Repeat of screening procedures Medical history Physical exam Questions about vision and general health Dark adapted fundus perimetry: Participants sit in the dark for 40 minutes. Then they sit at a machine that shines lights in the eyes. Dark adaption testing: Participants sit in the dark for 45 minutes. The pupils are dilated. They push a button when they see light in a machine for up to 1 hour. Participants will have annual visits for up to 5 years to repeat the tests in the first visit. Participant data may be shared for other research. ...
“We hope to learn more about the safety and feasibility of using your own (autologous) stem cells extracted from your bone marrow.”
open to eligible people ages 18-100
This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem cells from bone marrow into the eye as treatment for patients who are irreversibly blind from various retinal conditions.
Study of the Effectiveness and Safety of Brolucizumab Compared to Aflibercept for Neovascular Age-related Macular Degeneration
open to eligible people ages 50 years and up
The study is a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with nAMD (neovascular age related macular degeneration) who have not previously received anti-VEGF (vascular endothelial growth factor) treatment. Patients who consent will undergo screening assessments to evaluate their eligibility based on the inclusion and exclusion criteria.
Sacramento, California and other locations